Kunihiko Miyazaki, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 45 | 2024 | 13382 | 1.780 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 22 | 2024 | 5318 | 1.400 |
Why?
|
Spinal Neoplasms | 4 | 2024 | 703 | 0.960 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2023 | 101 | 0.830 |
Why?
|
Growth Differentiation Factor 6 | 1 | 2022 | 8 | 0.820 |
Why?
|
Osteolysis | 1 | 2019 | 275 | 0.580 |
Why?
|
Carcinoma, Small Cell | 2 | 2010 | 420 | 0.570 |
Why?
|
Lung Diseases, Interstitial | 3 | 2010 | 918 | 0.540 |
Why?
|
Small Cell Lung Carcinoma | 5 | 2024 | 423 | 0.530 |
Why?
|
Quinazolines | 3 | 2018 | 1371 | 0.490 |
Why?
|
Gait | 1 | 2019 | 810 | 0.450 |
Why?
|
Protein Kinase Inhibitors | 9 | 2024 | 5662 | 0.430 |
Why?
|
Adenocarcinoma | 5 | 2022 | 6340 | 0.410 |
Why?
|
Scoliosis | 1 | 2019 | 790 | 0.400 |
Why?
|
Carcinoma, Large Cell | 1 | 2010 | 113 | 0.330 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2016 | 1624 | 0.310 |
Why?
|
Mutation | 15 | 2024 | 30006 | 0.310 |
Why?
|
Acrylamides | 4 | 2022 | 259 | 0.290 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 11732 | 0.270 |
Why?
|
Japan | 2 | 2020 | 1373 | 0.240 |
Why?
|
Mucin-1 | 1 | 2010 | 537 | 0.240 |
Why?
|
Gene Rearrangement | 2 | 2020 | 1125 | 0.240 |
Why?
|
Urologic Neoplasms | 1 | 2008 | 314 | 0.230 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2008 | 592 | 0.230 |
Why?
|
Aniline Compounds | 4 | 2022 | 1073 | 0.220 |
Why?
|
Appendiceal Neoplasms | 1 | 2005 | 155 | 0.210 |
Why?
|
Genes, erbB-1 | 2 | 2022 | 162 | 0.210 |
Why?
|
Muscular Dystrophies | 1 | 2005 | 390 | 0.200 |
Why?
|
Aggrecans | 1 | 2022 | 89 | 0.200 |
Why?
|
Hyperinsulinism | 1 | 2005 | 400 | 0.190 |
Why?
|
Aged, 80 and over | 17 | 2024 | 58946 | 0.190 |
Why?
|
Collagen Type II | 1 | 2022 | 148 | 0.190 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2016 | 5300 | 0.190 |
Why?
|
Humans | 64 | 2024 | 761098 | 0.170 |
Why?
|
Neoplasms, Second Primary | 1 | 2008 | 1051 | 0.170 |
Why?
|
Spinal Cord Compression | 1 | 2022 | 234 | 0.170 |
Why?
|
Neoplasms, Complex and Mixed | 1 | 2020 | 35 | 0.170 |
Why?
|
MafB Transcription Factor | 1 | 2019 | 25 | 0.170 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2020 | 65 | 0.170 |
Why?
|
Retrospective Studies | 15 | 2024 | 80673 | 0.170 |
Why?
|
Pleural Effusion, Malignant | 1 | 2020 | 106 | 0.160 |
Why?
|
Meningeal Carcinomatosis | 1 | 2019 | 63 | 0.160 |
Why?
|
Bone Neoplasms | 2 | 2021 | 2527 | 0.160 |
Why?
|
Aged | 25 | 2024 | 169266 | 0.150 |
Why?
|
Lung, Hyperlucent | 1 | 2017 | 5 | 0.150 |
Why?
|
Emphysema | 1 | 2020 | 238 | 0.140 |
Why?
|
Kidney Diseases, Cystic | 1 | 2019 | 182 | 0.140 |
Why?
|
Pleural Effusion | 1 | 2020 | 341 | 0.140 |
Why?
|
Spine | 1 | 2023 | 1128 | 0.140 |
Why?
|
Carboplatin | 2 | 2017 | 793 | 0.140 |
Why?
|
Fatal Outcome | 4 | 2019 | 1837 | 0.130 |
Why?
|
Middle Aged | 24 | 2024 | 220835 | 0.130 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2020 | 279 | 0.130 |
Why?
|
Mycobacterium avium Complex | 1 | 2016 | 60 | 0.130 |
Why?
|
Mycobacterium avium-intracellulare Infection | 1 | 2016 | 76 | 0.130 |
Why?
|
Cervical Vertebrae | 1 | 2021 | 976 | 0.120 |
Why?
|
Cisplatin | 1 | 2020 | 1651 | 0.120 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2010 | 4021 | 0.110 |
Why?
|
Female | 30 | 2024 | 392458 | 0.110 |
Why?
|
Immunotherapy | 3 | 2024 | 4642 | 0.110 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2019 | 732 | 0.110 |
Why?
|
Prognosis | 8 | 2024 | 29672 | 0.110 |
Why?
|
China | 1 | 2019 | 2374 | 0.110 |
Why?
|
Pulmonary Eosinophilia | 1 | 2013 | 78 | 0.110 |
Why?
|
Male | 26 | 2024 | 360675 | 0.100 |
Why?
|
Palliative Care | 3 | 2024 | 3593 | 0.100 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2021 | 9278 | 0.100 |
Why?
|
Treatment Outcome | 7 | 2023 | 64670 | 0.100 |
Why?
|
Neoplasm Metastasis | 5 | 2020 | 4908 | 0.100 |
Why?
|
Biological Products | 1 | 2021 | 913 | 0.100 |
Why?
|
Rats | 3 | 2023 | 23713 | 0.100 |
Why?
|
Smoking | 2 | 2024 | 9055 | 0.090 |
Why?
|
Hemoptysis | 1 | 2012 | 151 | 0.090 |
Why?
|
Radiography, Thoracic | 4 | 2020 | 1303 | 0.090 |
Why?
|
Postoperative Complications | 2 | 2024 | 15634 | 0.090 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2022 | 4340 | 0.090 |
Why?
|
Antineoplastic Agents | 5 | 2020 | 13630 | 0.090 |
Why?
|
Adult | 14 | 2024 | 221083 | 0.090 |
Why?
|
Lung | 3 | 2020 | 9979 | 0.090 |
Why?
|
Spinal Fusion | 1 | 2019 | 1294 | 0.090 |
Why?
|
Paclitaxel | 1 | 2017 | 1730 | 0.080 |
Why?
|
Idiopathic Interstitial Pneumonias | 1 | 2009 | 24 | 0.080 |
Why?
|
Carcinoma, Giant Cell | 1 | 2008 | 5 | 0.080 |
Why?
|
Alleles | 1 | 2020 | 6857 | 0.080 |
Why?
|
Paraneoplastic Syndromes | 1 | 2010 | 155 | 0.080 |
Why?
|
Bronchogenic Cyst | 1 | 2008 | 28 | 0.080 |
Why?
|
Bronchopulmonary Sequestration | 1 | 2008 | 43 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6482 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 9 | 2020 | 20600 | 0.070 |
Why?
|
Eosinophils | 2 | 2021 | 951 | 0.070 |
Why?
|
Lymphatic Diseases | 1 | 2008 | 320 | 0.070 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2012 | 830 | 0.060 |
Why?
|
Diagnosis, Differential | 5 | 2019 | 12975 | 0.060 |
Why?
|
Lung Diseases | 1 | 2016 | 1909 | 0.060 |
Why?
|
Exanthema | 1 | 2010 | 503 | 0.060 |
Why?
|
Risk Factors | 5 | 2024 | 74219 | 0.060 |
Why?
|
DNA Fragmentation | 1 | 2005 | 237 | 0.060 |
Why?
|
Trinucleotide Repeats | 1 | 2005 | 257 | 0.060 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 3200 | 0.050 |
Why?
|
Receptors, Adiponectin | 1 | 2023 | 81 | 0.050 |
Why?
|
Databases, Factual | 1 | 2018 | 7969 | 0.050 |
Why?
|
Asthma | 1 | 2021 | 6229 | 0.050 |
Why?
|
Epidural Space | 1 | 2022 | 122 | 0.050 |
Why?
|
Notochord | 1 | 2020 | 37 | 0.050 |
Why?
|
Child, Preschool | 1 | 2023 | 42217 | 0.050 |
Why?
|
Paralysis | 1 | 2022 | 250 | 0.040 |
Why?
|
Integrin alpha5beta1 | 1 | 2020 | 36 | 0.040 |
Why?
|
Exudates and Transudates | 1 | 2020 | 174 | 0.040 |
Why?
|
Neoplasm Staging | 3 | 2020 | 11118 | 0.040 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2008 | 2197 | 0.040 |
Why?
|
Quinazolinones | 1 | 2021 | 221 | 0.040 |
Why?
|
Gelatin | 1 | 2020 | 221 | 0.040 |
Why?
|
Young Adult | 2 | 2019 | 59199 | 0.040 |
Why?
|
Cause of Death | 1 | 2009 | 3688 | 0.040 |
Why?
|
Organoplatinum Compounds | 1 | 2020 | 407 | 0.040 |
Why?
|
Age Distribution | 1 | 2024 | 2873 | 0.040 |
Why?
|
Abdominal Pain | 1 | 2005 | 1071 | 0.040 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2020 | 714 | 0.040 |
Why?
|
Animals | 4 | 2023 | 168083 | 0.040 |
Why?
|
Microspheres | 1 | 2020 | 783 | 0.040 |
Why?
|
Adiponectin | 1 | 2023 | 1106 | 0.040 |
Why?
|
Decompression, Surgical | 1 | 2022 | 607 | 0.030 |
Why?
|
Delayed-Action Preparations | 1 | 2020 | 961 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2021 | 1597 | 0.030 |
Why?
|
Time Factors | 1 | 2018 | 39953 | 0.030 |
Why?
|
Muscles | 1 | 2021 | 1567 | 0.030 |
Why?
|
Amino Acids | 1 | 2022 | 1703 | 0.030 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2018 | 753 | 0.030 |
Why?
|
Bronchoalveolar Lavage | 1 | 2016 | 129 | 0.030 |
Why?
|
Peptides | 1 | 2008 | 4353 | 0.030 |
Why?
|
Mechanotransduction, Cellular | 1 | 2020 | 528 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2020 | 1737 | 0.030 |
Why?
|
Survival Rate | 1 | 2010 | 12727 | 0.030 |
Why?
|
Autopsy | 1 | 2019 | 1010 | 0.030 |
Why?
|
Peptide Fragments | 1 | 2008 | 5103 | 0.030 |
Why?
|
Age Factors | 2 | 2024 | 18385 | 0.030 |
Why?
|
Hydrogels | 1 | 2020 | 720 | 0.030 |
Why?
|
Probability | 1 | 2020 | 2478 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2014 | 5809 | 0.030 |
Why?
|
Incidental Findings | 1 | 2019 | 698 | 0.030 |
Why?
|
Mice, Nude | 1 | 2020 | 3604 | 0.030 |
Why?
|
Tumor Burden | 1 | 2020 | 1892 | 0.030 |
Why?
|
Anti-Inflammatory Agents | 1 | 2023 | 1812 | 0.030 |
Why?
|
Exons | 1 | 2019 | 2380 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2020 | 2706 | 0.030 |
Why?
|
Mice, Inbred BALB C | 1 | 2020 | 6198 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2020 | 1605 | 0.020 |
Why?
|
Quality of Life | 2 | 2021 | 13362 | 0.020 |
Why?
|
Insulin Resistance | 1 | 2005 | 3951 | 0.020 |
Why?
|
Biopsy | 2 | 2016 | 6781 | 0.020 |
Why?
|
Bronchoscopy | 1 | 2016 | 909 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2508 | 0.020 |
Why?
|
Prospective Studies | 2 | 2024 | 54419 | 0.020 |
Why?
|
Radiography | 1 | 2019 | 6975 | 0.020 |
Why?
|
Survival Analysis | 1 | 2020 | 10083 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2024 | 15845 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2023 | 9185 | 0.020 |
Why?
|
Incidence | 1 | 2024 | 21357 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2020 | 12058 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10552 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 12467 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2020 | 10421 | 0.010 |
Why?
|
Logistic Models | 1 | 2019 | 13254 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2022 | 22157 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2017 | 4060 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2020 | 16947 | 0.010 |
Why?
|
Adolescent | 2 | 2017 | 88271 | 0.010 |
Why?
|
Disease Progression | 1 | 2020 | 13506 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 20120 | 0.010 |
Why?
|
Pneumonectomy | 1 | 2008 | 1118 | 0.010 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2008 | 1895 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2007 | 36418 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2008 | 6507 | 0.010 |
Why?
|
Mice | 1 | 2020 | 81324 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2020 | 20981 | 0.010 |
Why?
|
HIV Infections | 1 | 2008 | 17349 | 0.000 |
Why?
|